Prolia (Denosumab) Cost in Idaho 2026

What Does Prolia (Denosumab) Cost in Idaho in 2026?

At Idaho retail pharmacies, the cash-pay price for a single Prolia (denosumab) 60 mg/1 mL prefilled syringe is approximately $1 to 500 in 2026. Because the standard dosing schedule is one injection every six months, the annual out-of-pocket cost without insurance or assistance programs is roughly $3,000. That figure reflects the Amgen manufacturer list price, which has held near this level across most U.S. retail markets and is consistent with pharmacy benefit data compiled from Idaho chains such as Smith's, Walgreens Boise, and independent rural pharmacies in Twin Falls and Coeur d'Alene.

Denosumab is a fully human monoclonal antibody that targets RANK ligand (RANKL), reducing osteoclast-mediated bone resorption. Because it is a biologic, no traditional small-molecule generic is available in the United States as of mid-2025. Biosimilars have entered earlier-stage regulatory review, but none had achieved broad Idaho formulary placement as of this writing. Until a biosimilar reaches meaningful market penetration, brand list pricing largely sets the ceiling for what Idaho patients pay at the pharmacy counter without assistance.

The $1,500 figure is the list price. Actual negotiated rates between pharmacy benefit managers and payers differ. Patients with commercial insurance often pay a copay of $0 to $200 per injection after the savings card is applied (see the Amgen savings-card section below). Medicare Part D beneficiaries face a distinct cost structure explained further in the insurance section. Prolia FDA prescribing information confirms the 60 mg subcutaneous dose every six months as the approved osteoporosis regimen.

Does Idaho Medicaid Cover Prolia?

Idaho Medicaid does not cover Prolia (denosumab) for the osteoporosis indication as of 2026. This gap is significant because Idaho's Medicaid population skews rural and lower-income, two demographics with elevated osteoporosis burden and limited access to specialty pharmacies that might offer alternative pathways.

The Idaho Department of Health and Welfare publishes a preferred drug list (PDL) that governs outpatient pharmacy benefits under the state Medicaid program. Denosumab is not listed as a preferred or non-preferred covered drug for osteoporosis on the current PDL. Prior authorization requests for osteoporosis have been routinely denied based on available step-therapy requirements that place oral bisphosphonates (alendronate, risedronate) and injectable zoledronic acid ahead of denosumab in the treatment ladder.

Providers may attempt a prior authorization appeal citing clinical contraindications to bisphosphonates, such as severe renal impairment (eGFR <35 mL/min/1.73 m²) or intolerance, but approval is not guaranteed and denials remain common. For Idaho Medicaid patients who cannot tolerate bisphosphonates and cannot afford brand Prolia, compounded denosumab from a licensed 503A pharmacy (discussed below) represents the most accessible option, though it requires a valid prescription from a licensed prescriber.

Patients enrolled in the Dual Eligible Special Needs Plan (D-SNP), which coordinates Medicare and Medicaid benefits, may have a different experience because Medicare Part B can cover Prolia when administered in a physician's office rather than dispensed at retail. That Part B pathway is explored in the insurance section.

Which Insurance Plans Cover Prolia in Idaho?

Coverage depends on whether the drug is billed under Part B (medical benefit) or Part D (pharmacy benefit), and under commercial insurance, on the specific plan's formulary tier.

Medicare Part B. When a physician or qualified provider administers Prolia in an office or outpatient clinic setting, it is billed as a medical drug under Medicare Part B rather than as a pharmacy claim. Part B covers 80% of the Medicare-approved amount after the deductible. The patient's 20% coinsurance applies. For a $1,500 list-price drug, that coinsurance could approach $200 to $300 per injection depending on negotiated Medicare rates, though Medigap supplemental plans often cover that coinsurance entirely. This Part B pathway is the primary coverage route for most Idaho Medicare beneficiaries.

Medicare Part D. If a patient fills Prolia at a retail pharmacy rather than receiving it in-office, Part D applies. Denosumab falls on Tier 4 or Tier 5 specialty drug tiers in most Part D formularies, producing coinsurance of 25% to 33% during the coverage phase. Starting in 2025, the Inflation Reduction Act capped out-of-pocket Part D costs at $2,000 annually, which meaningfully reduces catastrophic exposure for high-cost biologics like Prolia.

Commercial insurance in Idaho. Blue Cross of Idaho, Regence BlueShield of Idaho, and Select Health (the dominant carriers on Idaho's Your Health Idaho exchange) generally cover Prolia for osteoporosis when the patient meets clinical criteria. Those criteria typically include a DEXA T-score of -2.5 or below, or a prior fragility fracture. Step therapy requiring a prior bisphosphonate trial of at least 12 months is common before denosumab approval.

The American Association of Clinical Endocrinology (AACE) 2020 guidelines state: "Denosumab is recommended as first-line therapy for patients at very high risk of fracture, including those with a prior hip or vertebral fracture." (AACE Clinical Practice Guidelines) Citing this language in a prior authorization appeal can override step-therapy requirements when fracture risk documentation supports it.

How Does the Amgen Savings Card Work in Idaho?

The Amgen Assist 360 savings card is available to commercially insured Idaho patients who are not enrolled in a government-funded program (Medicare, Medicaid, CHIP, or any federal or state employee health plan). Eligible patients may pay as little as $0 per Prolia dose, with Amgen covering the balance up to a per-dose cap.

To activate the card, patients or their prescriber's office enrolls at the Amgen Assist 360 portal. The card is then presented at the pharmacy or to the administering physician's office at the time of each injection. The prescriber's office staff typically handles this enrollment during routine prior authorization workflows.

Key eligibility limitations for Idaho patients:

• Must have commercial (private) insurance that covers Prolia.
• Must reside in the United States and be at least 18 years old.
• Federal beneficiaries (Medicare, VA, Medicaid) are excluded.
• The card does not substitute for insurance; the drug must be a covered benefit.

For Idaho patients who are uninsured and do not qualify for the savings card, Amgen's patient assistance program (Amgen Safety Net Foundation) provides Prolia at no cost to patients whose household income is at or below 500% of the federal poverty level. The application process requires income verification and a prescriber's attestation of medical necessity.

Is Compounded Denosumab Legal in Idaho?

Compounded denosumab is available from licensed 503A compounding pharmacies in Idaho. This is a meaningful distinction from many other states where access is more restricted. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed compounding pharmacy may prepare a drug product on a patient-specific basis from a valid prescription when a licensed prescriber determines that the commercially available product does not meet a patient's clinical needs.

Denosumab is a large-molecule biologic, and the FDA has expressed concern about compounded biologics given the complexity of replicating folding, glycosylation, and immunogenicity profiles. The FDA has not placed denosumab on its "essentially a copy" prohibited list for 503A compounding, but prescribers and patients should understand that compounded denosumab is not FDA-approved, has not undergone the same clinical validation as Prolia, and its potency and sterility depend entirely on the compounding pharmacy's quality practices.

The HealthRX clinical team uses the following framework when evaluating a patient's suitability for compounded denosumab in place of brand Prolia:

1. Financial hardship documented. Cash price of brand Prolia is unaffordable, no Amgen savings card eligibility exists, and no Medicare Part B administration pathway is available.
2. Prescriber has evaluated fracture risk. A current DEXA scan (within 24 months) shows T-score <-2.5 or the patient has a prior fragility fracture, confirming that RANKL inhibition is the medically appropriate choice rather than an oral bisphosphonate.
3. Pharmacy verification. The 503A pharmacy is licensed in Idaho, accredited by PCAB (Pharmacy Compounding Accreditation Board) or equivalent, and can provide a certificate of analysis for each lot.
4. Prescriber monitors for efficacy. Given the absence of bioequivalence data for compounded denosumab, a repeat DEXA scan at 12 months (rather than the standard 24 months with brand Prolia) confirms bone mineral density response.
5. Hypocalcemia screening. Both brand and compounded denosumab carry a risk of hypocalcemia. Baseline serum calcium and vitamin D levels are checked before the first dose, per FDA labeling guidance.

Idaho patients interested in compounded denosumab should request that their prescriber confirm the pharmacy's licensure and sterility testing practices before proceeding.

Clinical Evidence Supporting Denosumab for Osteoporosis

The regulatory basis for Prolia's approval and its dominant position in fracture-prevention guidelines rests primarily on the FREEDOM trial, published in the New England Journal of Medicine in 2009. FREEDOM enrolled 7,868 postmenopausal women aged 60 to 90 with a lumbar spine or total hip T-score between -2.5 and -4.0. Participants received denosumab 60 mg subcutaneously every six months or placebo for 36 months. Cummings SR et al., NEJM 2009

Key FREEDOM results:

• New vertebral fractures occurred in 2.3% of denosumab-treated women versus 7.2% in the placebo group, a 68% relative risk reduction (P<0.001).
• Hip fractures occurred in 0.7% of denosumab patients versus 1.2% placebo, a 40% relative risk reduction (P<0.05).
• Nonvertebral fractures were reduced by 20% (P<0.05).
• Bone mineral density at the lumbar spine increased by 9.2% from baseline in the denosumab group at 36 months.

These results established denosumab as one of the most effective pharmacologic agents for fracture prevention in postmenopausal osteoporosis. The FREEDOM Extension study, which followed participants for up to 10 years of open-label denosumab, showed continued BMD gains without a plateau through year 10. (FREEDOM Extension, JBMR 2012)

A clinically important caveat specific to discontinuation: denosumab suppresses bone turnover only while on therapy. Stopping denosumab without transitioning to a bisphosphonate produces a rebound increase in bone turnover markers and rapid BMD loss. Bone HG et al., Lancet Diabetes Endocrinol 2017 showed that patients who discontinued denosumab lost all BMD gains within 12 to 18 months and faced increased vertebral fracture risk. Idaho prescribers and patients using either brand or compounded denosumab must plan a transition regimen before stopping.

Can Idaho Patients Get Prolia Via Telehealth?

Yes. Idaho law permits telehealth prescribing of Prolia (denosumab) for established patients with appropriate clinical documentation. An Idaho-licensed provider conducting a telehealth visit can review a current DEXA scan, assess fracture risk using the FRAX algorithm, and issue a prescription for denosumab to be administered at a local pharmacy, physician's office, or infusion center.

The FRAX tool, developed by the World Health Organization WHO FRAX tool, JBMR 2008, calculates a 10-year probability of major osteoporotic fracture and hip fracture. AACE guidelines recommend pharmacologic treatment when the 10-year major fracture probability exceeds 20% or the 10-year hip fracture probability exceeds 3%. Meeting either threshold supports a telehealth prescriber's clinical documentation for initiating denosumab.

For rural Idaho patients in counties like Custer, Lemhi, or Clark, where the nearest bone density center may be 90 miles or more away, telehealth prescribing allows a prior DEXA result obtained at a regional hospital to be reviewed remotely. The prescriber can initiate therapy and arrange for a nurse or local clinic to administer the subcutaneous injection on schedule.

HealthRX clinicians licensed in Idaho can conduct this evaluation fully online. After reviewing DEXA results, labs (including serum calcium and 25-OH vitamin D), and fracture history, the prescriber issues a prescription that the patient fills at the pharmacy of their choice or through a HealthRX-affiliated compounding partner.

Hypocalcemia Risk: What Idaho Patients Need to Know Before Starting

Hypocalcemia is the most serious acute adverse effect of denosumab. It occurs because RANKL inhibition dramatically reduces bone resorption, creating a net calcium uptake into bone and dropping serum calcium. Patients with existing vitamin D deficiency, renal impairment, or hypoparathyroidism are at highest risk.

The Prolia FDA label requires per FDA prescribing information:

• Correct pre-existing hypocalcemia before initiating denosumab.
• Adequate calcium and vitamin D supplementation throughout treatment. The label recommends at least 1 to 000 mg calcium and 400 IU vitamin D daily.
• Monitoring of serum calcium within two weeks of the first dose in high-risk patients (those with renal impairment, hypoparathyroidism, or malabsorption syndromes).

Idaho's rural population includes many patients with limited sun exposure during the long winters in northern Idaho, contributing to high rates of vitamin D insufficiency. A 2011 NHANES analysis found that 41.6% of U.S. adults had serum 25-OH vitamin D below 20 ng/mL. (Forrest KY, Nutr Res 2011, PubMed) Idaho patients starting denosumab should have a 25-OH vitamin D level checked and, if below 30 ng/mL, should be repleted with cholecalciferol (vitamin D3) at 2,000 to 4 to 000 IU daily for at least four weeks before the first injection.

Comparing Cost Pathways for Idaho Denosumab Patients in 2026

The table below summarizes the realistic cost scenarios for an Idaho patient receiving one Prolia injection per year (standard is two per year; this reflects per-injection cost for simplicity).

| Pathway | Estimated Per-Injection Cost (Idaho, 2026) | |---|---| | Cash pay, retail pharmacy | ~$1,500 | | Commercial insurance (post-savings card) | $0 to $200 | | Medicare Part B (office admin, 20% coinsurance) | ~$150 to $300 | | Medicare Part D (Tier 4/5, pre-$2,000 cap) | $375 to $500 | | Medicare Part D (after $2,000 OOP cap) | $0 | | Amgen Safety Net Foundation (income-qualified) | $0 | | Compounded denosumab (503A, prescription required) | Varies (typically substantially below $1,500) |

Annual cost (two injections) at cash pay is approximately $3,000. Annual cost for a Medicare Part B patient with a Medigap plan covering coinsurance is potentially $0 after plan premiums are considered.

What Happens If You Miss a Prolia Injection?

Denosumab's pharmacodynamic effect on bone resorption follows a predictable time course. Bone turnover markers begin rising within six months of a missed dose, and BMD starts declining by month nine to twelve. Bone HG et al., 2017 documented multiple vertebral fractures in patients who were late for or skipped injections by more than two months.

Endocrine Society guidelines state: "Patients should be counseled that denosumab must be administered on schedule and that a transition plan should be in place before considering discontinuation." (Eastell R, J Clin Endocrinol Metab 2019) If a patient misses an injection due to cost barriers, a prescriber should administer the delayed injection as soon as possible (within one month of the scheduled date) and then restart the six-month clock from that date.

Cost-driven non-adherence is particularly common in Idaho given the state's Medicaid coverage gap and the high proportion of rural patients without commercial insurance. Identifying an affordable pathway before the first injection, whether via the Amgen savings card, a 503A compounding pharmacy, or the Medicare Part B office-administration route, prevents the rebound fracture risk associated with irregular dosing.